title: [Testosterone substitution therapy in prostate cancer].
abstract: After the fourth decade of life the total testosterone level in men decreases continually. If clinical symptoms, such as decreased libido or erectile dysfunction are combined with a decreased serum testosterone level this is known as late onset hypogonadism (LOH) or partial androgen deficiency in the aging male (PADAM). In such cases testosterone substitution therapy is indicated. One important question is how to treat patients suffering from LOH but also have prostate cancer which was treated curatively in the past? Only relatively little data are available with small numbers of patients which show that testosterone substitution therapy is possible without an increased risk of a relapse in cases of cured prostate cancer. If the patient was cured it does not matter if radical prostatectomy or radiation therapy was used. It is mandatory that patients are well-informed about substitution therapy and that regular surveillance and controls are carried out during the therapy. For patients who still have prostate cancer which has not yet been treated or not yet cured decisions on whether the benefit of the testosterone replacement is greater than the potential risk of a progress of the disease have to be made on an individual case-specific basis.
authors.affiliation: Klinik für Urologie, Kliniken Maria Hilf GmbH, Viersener Str. 450, 41063 Mönchengladbach, Deutschland. angelika.kaminsky@mariahilf.de
authors.forename: A
authors.initials: A
authors.lastname: Kaminsky
authors.forename: H
authors.initials: H
authors.lastname: Sperling
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D047649:Andropause / Q000187:drug effects*; D000075202:Contraindications; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000503:physiopathology* / Q000532:radiotherapy / Q000601:surgery; D011788:Quality of Life; D012307:Risk Factors; D013739:Testosterone / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D013739:Testosterone; D017430:Prostate-Specific Antigen